Are there any studies on lurbinectedin's long term use with chemo?

What have studies shown about long-term use of lurbinectedin with chemotherapy?

Lurbinectedin is a novel antitumor agent that has shown promise in clinical trials for the treatment of small cell lung cancer (SCLC) [1]. When used in combination with chemotherapy, lurbinectedin has been demonstrated to have efficacy in patients with SCLC [2]. However, limited data are available on the long-term use of lurbinectedin with chemotherapy.

According to a phase 1 clinical trial, the most common side effects of lurbinectedin when combined with chemotherapy were neutropenia, anemia, and thrombocytopenia [3]. The trial also reported a median duration of treatment of 14 weeks, and most patients required dose interruptions due to adverse events [3]. Another phase 1 study reported similar findings, with a median treatment duration of 12 weeks and a high rate of dose interruptions [4].

A phase 2 clinical trial evaluated the efficacy and safety of lurbinectedin in patients with SCLC who had previously received chemotherapy [5]. The trial showed that lurbinectedin, in combination with topotecan, resulted in a significant improvement in overall response rate and overall survival compared to topotecan alone [5]. However, the trial had a limited follow-up period, with a median follow-up of 13 months [5].

While these studies provide evidence that lurbinectedin can be effective when used in combination with chemotherapy, they also highlight the need for further research on the long-term effects of lurbinectedin therapy [6]. Potential risks associated with long-term use include cardiac toxicity, hepatotoxicity, and pulmonary toxicity [6].

How does lurbinectedin fit into the treatment landscape for small cell lung cancer?

SCLC accounts for approximately 15% of all lung cancer cases and is often diagnosed at an advanced stage [7]. Treatment options for SCLC are limited, and patients with relapsed or refractory disease have a poor prognosis [7]. Lurbinectedin, in combination with chemotherapy, offers a new treatment approach for these patients.

What are the patent expiration details for lurbinectedin?

The patent for lurbinectedin is held by PharmaMar, a Spanish pharmaceutical company. According to DrugPatentWatch.com, the patent for lurbinectedin was granted in 2019 and is expected to expire in 2039 [8].

Sources:

[1] PharmacyTimes. (2020). Lurbinectedin: A Novel Antitumor Agent.

[2] Journal of Clinical Oncology. (2020). A Phase 1 Study of Lurbinectedin in Combination with Carboplatin in Patients with Advanced Small Cell Lung Cancer.

[3] Clinical Cancer Research. (2018). A Phase 1 Study of Lurbinectedin in Combination with Carboplatin in Patients with Advanced Small Cell Lung Cancer.

[4] Journal of Thoracic Oncology. (2020). A Phase 1 Study of Lurbinectedin in Combination with Carboplatin and Etoposide in Patients with Advanced Small Cell Lung Cancer.

[5] The Lancet Oncology. (2020). Lurbinectedin in combination with topotecan in patients with previously treated small cell lung cancer.

[6] Expert Opinion on Investigational Drugs. (2020). Lurbinectedin: A Review of Its Pharmacology and Clinical Potential.

[7] Journal of Clinical Oncology. (2020). Advances in the Management of Small Cell Lung Cancer.

[8] DrugPatentWatch.com. (2020). Lurbinectedin Patent Expiration Details.

Sources:

1. PharmacyTimes. (2020). Lurbinectedin: A Novel Antitumor Agent.
2. Journal of Clinical Oncology. (2020). A Phase 1 Study of Lurbinectedin in Combination with Carboplatin in Patients with Advanced Small Cell Lung Cancer.
3. Clinical Cancer Research. (2018). A Phase 1 Study of Lurbinectedin in Combination with Carboplatin in Patients with Advanced Small Cell Lung Cancer.
4. Journal of Thoracic Oncology. (2020). A Phase 1 Study of Lurbinectedin in Combination with Carboplatin and Etoposide in Patients with Advanced Small Cell Lung Cancer.
5. The Lancet Oncology. (2020). Lurbinectedin in combination with topotecan in patients with previously treated small cell lung cancer.
6. Expert Opinion on Investigational Drugs. (2020). Lurbinectedin: A Review of Its Pharmacology and Clinical Potential.
7. Journal of Clinical Oncology. (2020). Advances in the Management of Small Cell Lung Cancer.
8. DrugPatentWatch.com. (2020). Lurbinectedin Patent Expiration Details.